Lead Sponsor

AstraZeneca

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•Provision of informed consent prior to any study specific procedures
•Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a histopathology report
•Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with rectosigmoidoscopy score ≥ 2 during screening period
•Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of immunomodulators or Anti- TNF-α agents. etc.

•Disease limited to the rectum
•Toxic megacolon
•Crohn's Disease
•History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC
•Planned bowel surgery within 12 weeks from Visit 2
•Stool positive for C. difficile toxin at screening
•Primary Sclerosing Cholangitis
•History of gastrointestinal surgery within 8 weeks of Visit 2
•Any uncontrolled or clinically significant systemic disease
•Condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with study evaluation, procedures or completion
•Subjects with positive HBsAg, HBsAb, HBcAb or HCVAb serology at screening etc

Related studies

NCT06979336 · Ulcerative Colitis

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

NCT07593352 · IBD and Renal Involement, Chronic Kidney Disease, and more

NCT06100289 · Ulcerative Colitis, Crohn's Disease

NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients